Platinum based therapy
Poly-(ADP-ribose)-polymerase (PARP), . Although these agents have demonstrated notable success in treating different types of tumors, their effectiveness against cancers remains limited owing to increased drug resistance and the emergence .Background Platinum-resistant, recurrent ovarian cancer has an abysmal prognosis with limited treatment options.Combination therapy of platinum drugs can inhibit tumor growth and metastasis in an additive or synergistic manner, and can potentially reduce the systemic toxicity of platinum drugs and overcome platinum-resistance.
Platinum-based antineoplastic
platinum (Pt)-based agents are shown 1 ,4 5 7 13 45 53 64 67 81 87 104108112134.Balises :Platinum Based ChemotherapyOvarian CancerOxaliplatinCarboplatinIn this review, we focus on the mechanistic basis of the combinations of platinum-based drugs with other drugs to inspire the development of more promising .Balises :Cancer TreatmentOvarian cancerTherapyPlatinumBalises :ChemotherapyOvarian cancerJournal of Clinical Oncology
Efficacy of platinum-based chemotherapy in metastatic breast
These data suggest that, unlike BRCAmut cancers, where BRCA loss is a genetically fixed deficiency state, BRCA1meth cancers are highly adaptive to genotoxin exposure and, through reversal of promoter methylation, recover BRCA1 expression and become resistant to therapy.
We further found a specific augmented immune .Platinum-based combination chemotherapy nanomedicines.The side effects of platinum-based chemotherapy drugs: a . A search of available databases was conducted, based on specific inclusion and exclusion criteria, for trials conducted between January 2006 and January 2014.
Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. Platinum-based drugs cisplatin, carboplatin, and oxaliplatin are widely used for chemotherapeutic eradication of cancer.Platinum-based drugs have become a mainstay of cancer therapy; approximately half of all patients undergoing chemotherapeutic treatment receive a platinum drug (). A more personalized, holistic mental health treatment plan that’s designed specifically for you.Platinum-based chemotherapy in combination with taxanes has shown promising results in metastatic PC in a phase II study.Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval .The widespread use of platinum agents in the treatment of cancer began with the discovery of the antineoplastic activity of cisplatin by Barnett Rosenberg in the 1960s (). Patients and methods: Characterization of the second to sixth line therapy and its effects on survival was carried out, based on data of n = 1620 patients . HR-DDR analysis revealed the following mutation rates: 34% ARID1A; 16% ATM; 19% BRCA2; and 9% BRCA1.The platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by their severe, dose-limiting side effects (also referred to as adverse effects/events).Combination platinum-based chemotherapy is the standard of care for first-line treatment of advanced urothelial carcinoma in patients who are suitable .Patient recurrence more than 6 months after front-line platinum-based therapy is considered platinum-sensitive, whereas platinum-resistant recurrence occurs after less than 6 months (2,11,12).Structural modification of traditional platinum drugs, combination therapy using platinum drugs with other agents and improved delivery of platinum drug to tumor sites are major strategies developed to overcome existed problems in chemotherapy using traditional platinum drugs. Although some events prior to 2007 are included, the timeline .Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy.Key developments include the elucidation of mechanisms of tumour resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin . There is little information on the effectiveness of chemotherapy in higher treatment lines. There was no significant OS .As the most clinically used chemotherapy, platinum-based drugs, including cisplatin, carboplatin, and oxaliplatin, have been formulated into many nanoparticles. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.Platinum-based chemotherapy has a major role as first-line therapy for most patients with aUC.
Real-World Data About Treatment Outcomes for Patients with
The aim of the present study was to evaluate the effect of platinum-based therapy on the short-term efficacy and survival rate in patients with triple-negative breast cancer (TNBC).The rediscovery of platinum-based cancer therapy. This review summarizes the various modalities and current progress in platinum-based combination therapy.Platinum-based systematic therapy in triple-negative breast cancer - ScienceDirect.Balises :ChemotherapyNon-small cell lung cancerEpidermal growth factor receptor Several of them have undergone clinical evaluations [ 22 ], but none have been approved for clinical use.Sixty-five percent received Pt-based therapy at some point during their disease course. As platinum drugs are almost always used in combination with other drugs, .There is no consensus or guidelines to treat this tumor differently from pancreatic adenocarcinoma, but therapies based on gemcitabine and platinum chemotherapeutics such as cisplatin and oxaliplatin have been used based on results of a few case reports. In total, a cancer patient can experience a .Fortunately, the emergence of tetravalent platinum (Pt(IV)) prodrugs brought the Pt-based cancer therapy to a new stage.De très nombreux exemples de phrases traduites contenant platinum-based therapy – Dictionnaire français-anglais et moteur de recherche de traductions françaises.Pt-based nanodrugs, such as platinum nanoclusters, have novel anti-cancer mechanisms and great potential in tumor-targeted therapy and have shown promising results in clinical application.1186/s12885-016-2370-6 44 Platinum-based combination therapy represents a standard of care.Methods Patients who had progressed after platinum-based chemotherapy for advanced or metastatic disease or had progressed within 12 months after completion of platinum-based (neo)adjuvant therapy were given camrelizumab (200 mg intravenously every 3 weeks) plus famitinib (20 mg orally once daily).Our study shows that, in patients with advanced non-small-cell lung cancer with disease progression during or after first-line platinum-based therapy, ramucirumab plus docetaxel can significantly prolong survival compared with docetaxel, providing evidence for the role of a VEGFR-targeted therapy and offering patients with non-squamous and . Commercial Pt drugs are all in the form of bivalent Pt (Pt(II)) [ 47 , 48 ]. During the six months after the completion of major platinum-based chemotherapy, disease progression is usually closely related to .Balises :Ovarian CancerTherapyPlatinum
Platinum LED Therapy Lights Review: Honest Judgment
Lightfully is one of the first and only behavioral health . As platinum drugs are typically used in combination with other chemotherapeutics [43], platinum .Balises :Combination of Platinum DrugsCombination TherapyPublish Year:2020Balises :Cancer TreatmentPlatinum Based ChemotherapyScienceDirect
Alectinib in Resected ALK-Positive Non
To facilitate future therapeutic developments in these patients after treatment .
However, the side effects of . Nature Reviews Cancer 21 , 37–50 ( 2021) Cite this article.Balises :ChemotherapyCancer TreatmentNon-small cell lung cancerRheotaxis Corpus ID: 246714968. Platinum-based .Balises :Publish Year:2020Combination of Platinum DrugsCombination Therapy
The resurgence of platinum-based cancer chemotherapy
Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. However, the most promising activity of platinum therapy in CRPC patients is related to the presence of mutations in DNA repair genes.[PDF] Platinum-based drugs for cancer therapy and anti-tumor strategies | Semantic Scholar.govRecommandé pour vous en fonction de ce qui est populaire • AvisThe safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents.Materials and methods. However, the side effects of platinum drugs, . OS analysis showed no significant survival advantage based on stage or mutation type for any of the disease-specific cohorts.Understanding the complex response to platinum-based therapy will be crucial for developing improved methods for overcoming platinum resistance.KEYNOTE 189 and IMPOWER150 studies have shown that platinum-based chemotherapy combined with PD-1/PDL-1 immune checkpoint inhibitors results in better survival in patients with advanced NSCLC and established this combination therapy in the first-line setting [7, 8].
The rediscovery of platinum-based cancer therapy
It is believed that platinum-based drugs would play a more .
The initial response to platinum-based chemotherapy is as high as 80%, but in most advanced patients, final relapse and death are caused by acquired drug .Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC).Platinum LED Therapy Lights has 4 different Biomax light therapy devices that vary in size and the number of LED bulbs. Docetaxel is an established standard therapy after osimertinib and platinum-based doublet chemotherapy (Pt-doublet) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor gene (EGFR) mutation.Platinum-based drugs cisplatin, carboplatin, and oxaliplatin are widely used for chemotherapeutic eradication of cancer.orgCurrent status of platinum-based antitumor drugs - PubMedpubmed.Background: Despite recent progress in the treatment of ovarian cancer, the majority of patients eventually relapse.Balises :Cancer TreatmentPlatinum Based ChemotherapyMetastatic Breast CancerAuteur : Sven Rottenberg, Carmen Disler, Paola Perego
Platinum-based drugs for cancer therapy and anti-tumor strategies
A more recent comparison to topotecan as second-line therapy in patients with at least a 3-month CTFI demonstrated an improvement in PFS with platinum-etoposide retreatment but no . Breast Cancer Research (2022) Metastatic breast cancer (MBC) is frequently managed by platinum-based chemotherapy during the disease .Platinum-based therapy of patients with gastrointestinal cancers that harbor homologous recombination DNA damage response (HR-DDR) mutations: A single institutional .
In the advanced disease setting, platinum-based regimens were the first to improve survival as well as quality of life when compared with best supportive care.Balises :ChemotherapyCancer Drugs PlatinumCisplatin
Platinum-based drugs for cancer therapy and anti-tumor strategies
Balises :TherapyAnxiety disorderLos Angeles
In this subpopulation, the use of platinum represents a viable therapeutic .Balises :ChemotherapyCancer TreatmentOvarian cancerMolecular Mechanisms
Genomic and epigenomic BRCA alterations predict adaptive
Platinum-based agents with respect to their structure, mechanism of . Sven Rottenberg, Carmen Disler & Paola Perego. Prior epidermal growth factor receptor (EGFR) tyrosine .Balises :ChemotherapyCancer TreatmentPlatinum CancerCediranib and Olaparib After one simple step of oxidation, Pt(IV)-dihydroxy (tetravalent Pt) could be obtained [ 17 , 49 ].
.png?fit=fill&fill=solid&w=440&h=400)
